Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $34.60.

A number of research analysts have recently commented on VRDN shares. Needham & Company LLC reissued a "buy" rating and issued a $30.00 target price on shares of Viridian Therapeutics in a report on Thursday, May 9th. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, May 9th. Oppenheimer dropped their target price on shares of Viridian Therapeutics from $36.00 to $31.00 and set an "outperform" rating for the company in a report on Thursday, May 9th. HC Wainwright dropped their target price on shares of Viridian Therapeutics from $37.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 9th. Finally, Wedbush increased their target price on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a report on Wednesday, February 28th.

Viridian Therapeutics Price Performance

VRDN traded down $0.05 on Friday, hitting $12.11. 908,812 shares of the stock were exchanged, compared to its average volume of 923,674. Viridian Therapeutics has a 12 month low of $10.93 and a 12 month high of $28.35. The business has a 50-day moving average of $15.27 and a two-hundred day moving average of $17.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. The firm has a market capitalization of $772.86 million, a price-to-earnings ratio of -2.69 and a beta of 1.14.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.28. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.09 million. During the same quarter in the prior year, the business posted ($1.61) earnings per share. Viridian Therapeutics's revenue was down 26.5% compared to the same quarter last year. Sell-side analysts forecast that Viridian Therapeutics will post -3.61 EPS for the current fiscal year.

Institutional Trading of Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. Ameritas Investment Partners Inc. increased its position in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock valued at $87,000 after purchasing an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Viridian Therapeutics by 122.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company's stock valued at $182,000 after purchasing an additional 4,610 shares during the period. Arizona State Retirement System acquired a new stake in Viridian Therapeutics during the 4th quarter valued at approximately $208,000. Principal Financial Group Inc. increased its position in Viridian Therapeutics by 9.7% during the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company's stock valued at $209,000 after purchasing an additional 1,058 shares during the period. Finally, Raymond James & Associates increased its position in Viridian Therapeutics by 71.1% during the 3rd quarter. Raymond James & Associates now owns 15,164 shares of the company's stock valued at $233,000 after purchasing an additional 6,303 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.